GLP-1 Availability & Access (2026)
How patients actually access GLP-1 drugs in 2026 — from the new oral semaglutide pill to direct-to-patient cash-pay programs — as telehealth compounding routes narrow.
ExpandingLast verified 16 minutes ago
- CurrentOral semaglutide (Wegovy pill)Launched January 2026 — Needle-free oral option.
Needle-free oral option.
- CurrentDirect-to-patient (LillyDirect)Available — Zepbound self-pay
- CurrentDirect-to-patient (NovoCare)Available — Wegovy ~$349 cash-pay
- CurrentTelehealth compounded accessSharply reduced after FDA crackdown
How we keep this current
Our AI Librarian periodically re-checks each line against primary sources — FDA notices, manufacturer announcements, and clinical-trial registries — and re-stamps the "last verified" date above. Fast-moving regulatory facts can still change between checks; always confirm against the linked primary source before relying on any single line.